Further validation of Novacyt’s expertise in
developing assays for clinical applications
Novacyt Signs Assay Development Contract for Diagnosis of Respiratory Infections with GenePOC
Paris, France and Camberley, UK – 22 March 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its molecular testing division, Primerdesign, has entered into a clinical assay development contract with GenePOC Inc., a Canada-based company and member of the Debiopharm Group™, which specialises in the development and manufacture of molecular diagnostic devices for the detection of infectious diseases closer to the patient.